We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-13.34%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.15B
AUM Growth
-$354M
Cap. Flow
+$252M
Cap. Flow %
11.69%
Top 10 Hldgs %
47.71%
Holding
76
New
9
Increased
16
Reduced
38
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$76.6M
2
XLRN
Acceleron Pharma
XLRN
+$64.1M
3
AGEN
Agenus
AGEN
+$39M
4
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$30.8M
5
BEAM icon
Beam Therapeutics
BEAM
+$17.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$63.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$19.5M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
26
CRISPR Therapeutics
CRSP
$5.17B
$26.7M 1.24%
630,400
-369,600
-37% -$19.1M
BPMC
27
DELISTED
Blueprint Medicines
BPMC
$26.3M 1.22%
450,000
+105,000
+30% +$6.76M
CCXI
28
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$25.1M 1.17%
625,000
+375,000
+150% +$15.9M
ZYME icon
29
Zymeworks
ZYME
$1.67B
$24.8M 1.15%
700,000
– –
IGMS
30
DELISTED
IGM Biosciences
IGMS
$23.9M 1.11%
426,104
+269,704
+172% +$11.8M
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$394M
$21.9M 1.02%
1,568,550
-268,719
-15% -$5.32M
TWST icon
32
Twist Bioscience
TWST
$7.25B
$21M 0.98%
687,149
– –
AXNX
33
DELISTED
Axonics, Inc. Common Stock
AXNX
$20.3M 0.94%
800,000
-422,671
-35% -$12.6M
LKFT
34
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$19.7M 0.91%
98,603
-1,397
-1% -$301K
MYOV
35
DELISTED
Myovant Sciences Ltd.
MYOV
$19.6M 0.91%
2,600,000
+600,000
+30% +$6.73M
IMVTU
36
DELISTED
Immunovant, Inc. Units
IMVTU
$19.4M 0.9%
1,078,380
-1,620
-0.2% -$31.3K
TCDA
37
DELISTED
Tricida, Inc. Common Stock
TCDA
$19.3M 0.9%
877,975
-50,000
-5% -$1.61M
STSA
38
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$17.4M 0.81%
808,382
-50,000
-6% -$1.13M
ANAB icon
39
AnaptysBio
ANAB
$1.68B
$15.7M 0.73%
1,107,900
+742,900
+204% +$11.3M
CABA icon
40
Cabaletta Bio
CABA
$455M
$15.4M 0.71%
2,105,846
-13,286
-0.6% -$182K
ZLAB icon
41
Zai Lab
ZLAB
$2.62B
$14.9M 0.69%
289,092
+11,931
+4% +$622K
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.77B
$14.7M 0.68%
150,000
-100,000
-40% -$11.4M
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.4M 0.67%
350,000
-100,000
-22% -$5.55M
BEAM icon
44
Beam Therapeutics
BEAM
$2.84B
$14.3M 0.67%
+796,429
New +$17.3M
AKRO
45
DELISTED
Akero Therapeutics
AKRO
$13.6M 0.63%
642,539
-98,082
-13% -$2.1M
QTNT
46
DELISTED
Quotient Limited Ordinary Shares
QTNT
$12.5M 0.58%
79,038
-8,462
-10% -$2.22M
QURE icon
47
uniQure
QURE
$3.22B
$11.9M 0.55%
250,000
-150,000
-38% -$8.62M
ARGX icon
48
argenx
ARGX
$54.1B
$10.5M 0.49%
80,000
-20,000
-20% -$2.93M
QTTB icon
49
Q32 Bio
QTTB
$464M
$9.32M 0.43%
+33,333
New +$10.2M
SRNE
50
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$9.2M 0.43%
5,000,000
+1,000,000
+25% +$2.88M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Cormorant Asset Management held 76 positions worth $2.15B, down 14% from $2.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $252M of net new capital in Q1 2020, opening 9 new positions and adding to 16 existing holdings. Its largest new stake was Revolution Medicines: 2,767,078 shares worth $60.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $63.6M trimmed.

  • Cormorant Asset Management's largest Q1 2020 buy was Revolution Medicines: 2,767,078 shares worth $60.6M.
  • Cormorant Asset Management added most to Eidos Therapeutics, Inc. Common Stock in Q1 2020, an estimated $30.8M increase.
  • Cormorant Asset Management's biggest Q1 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $63.6M.
  • Cormorant Asset Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $2.15B portfolio in Q1 2020.
  • Cormorant Asset Management opened 9 new positions and closed 3 in Q1 2020.
  • Cormorant Asset Management's portfolio value fell 14% quarter-over-quarter to $2.15B.

Based on Cormorant Asset Management's 13F filing for Q1 2020, filed 15 May 2020.